MacroGenics, Inc. has announced updated efficacy and safety data from its Phase 2 TAMARACK clinical trial for vobramitamab duocarmazine, which is focused on treating metastatic castration-resistant prostate cancer. This information was presented at the European Society for Medical Oncology Congress in Barcelona, Spain, and accompanied by a press release on September 15, 2024. Additionally, the company held an investor conference call on September 16, 2024, to review the trial data and provide a general corporate update.
Proper names mentioned: - MacroGenics, Inc. - Jeffrey Peters (Senior Vice President and General Counsel at MacroGenics, Inc.) - European Society for Medical Oncology (ESMO) Congress - Nasdaq Global Select Market